MXPA04005942A - Composiciones y metodos de sintaxina 3. - Google Patents
Composiciones y metodos de sintaxina 3.Info
- Publication number
- MXPA04005942A MXPA04005942A MXPA04005942A MXPA04005942A MXPA04005942A MX PA04005942 A MXPA04005942 A MX PA04005942A MX PA04005942 A MXPA04005942 A MX PA04005942A MX PA04005942 A MXPA04005942 A MX PA04005942A MX PA04005942 A MXPA04005942 A MX PA04005942A
- Authority
- MX
- Mexico
- Prior art keywords
- syn3
- compositions
- methods
- aqueous
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen formulaciones en soluciones en solucion acuosa y no acuosa, que contiene agentes utiles para el tratamiento de cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34232901P | 2001-12-20 | 2001-12-20 | |
PCT/US2002/041198 WO2003053365A2 (en) | 2001-12-20 | 2002-12-20 | Syn3 compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04005942A true MXPA04005942A (es) | 2005-05-16 |
Family
ID=23341353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04005942A MXPA04005942A (es) | 2001-12-20 | 2002-12-20 | Composiciones y metodos de sintaxina 3. |
Country Status (13)
Country | Link |
---|---|
US (3) | US20030170216A1 (es) |
EP (1) | EP1456377B1 (es) |
JP (2) | JP4727923B2 (es) |
AU (1) | AU2002366809A1 (es) |
CA (1) | CA2470999C (es) |
CY (1) | CY1121982T1 (es) |
DK (1) | DK1456377T3 (es) |
ES (1) | ES2745068T3 (es) |
MX (1) | MXPA04005942A (es) |
PT (1) | PT1456377T (es) |
SI (1) | SI1456377T1 (es) |
TR (1) | TR201910060T4 (es) |
WO (1) | WO2003053365A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
CN1845932A (zh) * | 2003-06-04 | 2006-10-11 | 坎基股份有限公司 | 转染剂 |
SG166117A1 (en) * | 2003-12-10 | 2010-11-29 | Canji Inc | Methods and compositions for treatment of interferon-resistant tumors |
JP6013654B2 (ja) * | 2013-09-19 | 2016-10-25 | クルセル ホランド ベー ヴェー | 改良されたアデノウイルス製剤 |
US11311487B2 (en) | 2016-04-14 | 2022-04-26 | Trizell Ltd. | Viral vector stabilization |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105156B1 (en) | 1987-09-17 | 2006-09-12 | The Regents Of The University Of California | Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
ES2096614T3 (es) * | 1990-12-06 | 1997-03-16 | Hoechst Ag | Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de este compuesto como medicamento. |
US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US5795870A (en) | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
ES2189808T3 (es) | 1993-10-15 | 2003-07-16 | Cytrx Corp | Composiciones de aporte terapeutico y metodos de uso de las mismas. |
US6210939B1 (en) | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
EP0906110B1 (en) * | 1996-04-26 | 2004-12-22 | Merck & Co., Inc. | Dna vaccine formulations |
AU750207B2 (en) * | 1997-06-13 | 2002-07-11 | Cydex Pharmaceuticals, Inc. | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
DE19734860C2 (de) * | 1997-08-12 | 1999-12-16 | Bosch Gmbh Robert | Verfahren zur Bestimmung oxidierbarer Bestandteile in einem Gasgemisch |
CN100471522C (zh) * | 1998-03-13 | 2009-03-25 | 惠氏 | 聚核苷酸组合物及其制备方法与用途 |
US6166779A (en) * | 1999-04-27 | 2000-12-26 | Nucore Technology Inc. | Method for analog decimation of image signals |
EP1074248A1 (en) * | 1999-07-08 | 2001-02-07 | Arnold Hilgers | Delivery system for biological material |
JP2007526219A (ja) * | 2003-06-04 | 2007-09-13 | カンジ,インコーポレイテッド | トランスフェクション薬剤 |
CN1845932A (zh) * | 2003-06-04 | 2006-10-11 | 坎基股份有限公司 | 转染剂 |
WO2004108898A2 (en) | 2003-06-04 | 2004-12-16 | Canji, Inc. | Transfection agents |
SG166117A1 (en) | 2003-12-10 | 2010-11-29 | Canji Inc | Methods and compositions for treatment of interferon-resistant tumors |
JP2008203500A (ja) * | 2007-02-20 | 2008-09-04 | Fuji Xerox Co Ltd | ホログラム記録材料、ホログラム記録媒体、および、ホログラム記録方法 |
-
2002
- 2002-12-20 DK DK02805671.1T patent/DK1456377T3/da active
- 2002-12-20 US US10/329,043 patent/US20030170216A1/en not_active Abandoned
- 2002-12-20 MX MXPA04005942A patent/MXPA04005942A/es not_active Application Discontinuation
- 2002-12-20 PT PT02805671T patent/PT1456377T/pt unknown
- 2002-12-20 CA CA2470999A patent/CA2470999C/en not_active Expired - Lifetime
- 2002-12-20 EP EP02805671.1A patent/EP1456377B1/en not_active Expired - Lifetime
- 2002-12-20 WO PCT/US2002/041198 patent/WO2003053365A2/en active Application Filing
- 2002-12-20 SI SI200231095T patent/SI1456377T1/sl unknown
- 2002-12-20 JP JP2003554125A patent/JP4727923B2/ja not_active Expired - Lifetime
- 2002-12-20 AU AU2002366809A patent/AU2002366809A1/en not_active Abandoned
- 2002-12-20 TR TR2019/10060T patent/TR201910060T4/tr unknown
- 2002-12-20 ES ES02805671T patent/ES2745068T3/es not_active Expired - Lifetime
-
2010
- 2010-02-03 JP JP2010022598A patent/JP2010095549A/ja not_active Withdrawn
- 2010-07-19 US US12/838,795 patent/US9115374B2/en not_active Expired - Fee Related
-
2015
- 2015-07-13 US US14/798,277 patent/US20150313926A1/en not_active Abandoned
-
2019
- 2019-09-03 CY CY20191100923T patent/CY1121982T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2002366809A8 (en) | 2003-07-09 |
CA2470999C (en) | 2017-02-21 |
PT1456377T (pt) | 2019-09-10 |
CY1121982T1 (el) | 2020-10-14 |
EP1456377A4 (en) | 2010-07-07 |
DK1456377T3 (da) | 2019-09-23 |
WO2003053365A3 (en) | 2003-10-30 |
US9115374B2 (en) | 2015-08-25 |
AU2002366809A1 (en) | 2003-07-09 |
SI1456377T1 (sl) | 2019-09-30 |
US20150313926A1 (en) | 2015-11-05 |
US20030170216A1 (en) | 2003-09-11 |
CA2470999A1 (en) | 2003-07-03 |
JP2005513086A (ja) | 2005-05-12 |
US20100324126A1 (en) | 2010-12-23 |
JP2010095549A (ja) | 2010-04-30 |
ES2745068T3 (es) | 2020-02-27 |
EP1456377B1 (en) | 2019-06-12 |
TR201910060T4 (tr) | 2019-07-22 |
WO2003053365A2 (en) | 2003-07-03 |
JP4727923B2 (ja) | 2011-07-20 |
EP1456377A2 (en) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
CY1121982T1 (el) | Συνθεσεις syn3 και μεθοδοι | |
AP9901478A0 (en) | Compounds for the treatment of ischemia. | |
AU4768301A (en) | Synergistic methods and compositions for treating cancer | |
MXPA02012817A (es) | Drogas antineoplasicas liposomales y uso de las mismas. | |
HK1049787A1 (en) | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents | |
WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
AU2003293194A1 (en) | Compositions and methods for treating prostate cancer | |
ATE556706T1 (de) | Fettalkohol-arzneimittel-konjugate | |
WO2002076499A3 (en) | Combination treatment of pancreatic cancer | |
AU2003230750A1 (en) | Compositions and methods for treating cancer | |
AU2003225535A1 (en) | Methods and compositions for treating cancer | |
MXPA04003674A (es) | Uso mejorado de compuesto antitumoral en terapia de cancer. | |
WO2004058153A9 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
HK1040983A1 (en) | Quinones for treatment of diseases. | |
MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
AU2002367172A1 (en) | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
WO2004028474A3 (en) | Caspase inhibitors as anticancer agents | |
WO2002003979A3 (en) | Combination of 2-methoxyestradiol and an agent that increases intracellular superoxide anion | |
MXPA03001455A (es) | Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa. | |
HK1043058A1 (zh) | 異環磷酰胺芥子類似物及其用途 | |
TW200512009A (en) | Hair treatment compositions | |
TW200509972A (en) | Hair restorer, hair decay tendency inhibitor, cirrhosis treating agent and kidney treating agent | |
PL357179A1 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
EP1303300A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: SCHERING CORPORATION |
|
FA | Abandonment or withdrawal |